GlobalRPh Medical News Roundup Clinical developments for September 11-17

Clinical summaries

1. FDA approves the first gene therapy for Sanfilippo syndrome type A

What changed: FDA approved Fayuvi (rebisufligene etisparvovec-hopf) for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The one-time intravenous AAV9 gene therapy delivers a functional copy of the SGSH gene.

Why it matters for clinicians: Fayuvi is the first FDA-approved therapy designed to alter the underlying course of this progressive neurodevelopmental disease. In a single-arm study, treated children age 2 to 5 years maintained or improved cognitive function relative to an untreated historical cohort.

Practical clinical relevance: Treatment requires referral to an experienced metabolic or gene-therapy center. Patients receive corticosteroids beginning one day before infusion and continuing for at least eight weeks. Liver enzymes, blood counts, infusion reactions, and signs of thrombotic microangiopathy require monitoring.

Caveats: Evidence came from an open-label, single-arm study with historical controls. Long-term effects on development, functional independence, survival, and durability remain uncertain. AAV therapies also carry a theoretical long-term risk of genomic integration and tumor development.

FDA source

2. Pennsylvania measles outbreak expands and includes four measles-associated deaths

What changed: Pennsylvania reported 693 confirmed cases across 38 counties and four measles-associated deaths as of September 15. Nearly all reported patients were unvaccinated or had unknown vaccination status.

Why it matters for clinicians: This is Pennsylvania’s largest outbreak in decades and part of a wider national measles resurgence. Measles can cause pneumonia, encephalitis, pregnancy complications, and death, particularly among young children, pregnant patients, and immunocompromised people.

Practical clinical relevance: Screen for fever, cough, coryza, conjunctivitis, rash, vaccination history, and relevant exposure. Patients with suspected measles should call before arrival, be placed immediately in airborne isolation, and be reported promptly to public health authorities. Verify MMR immunity and provide catch-up vaccination when appropriate.

Caveats: Case totals change frequently and may underestimate the true burden. Death classification has also been subject to public dispute, although Pennsylvania applies a defined measles-associated death standard based on laboratory confirmation, timing, and the absence of a clearly unrelated cause.

PA Department of Health | September 15 case and mortality update

3. CDC reports nearly 20,000 domestically acquired Cyclospora infections

What changed: CDC increased its 2026 surveillance total to 19,883 laboratory-confirmed domestically acquired cases, 1,064 hospitalizations, and two deaths. This represents 1,438 additional cases and 74 additional hospitalizations since the September 1 update covered previously.

Why it matters for clinicians: The total greatly exceeds the 1,180 cases reported during the corresponding 2025 season. It includes the recently closed iceberg lettuce outbreak as well as cases associated with other or still-unidentified sources.

Practical clinical relevance: Consider cyclosporiasis in prolonged or relapsing watery diarrhea, particularly when accompanied by fatigue, anorexia, bloating, or weight loss. Request testing that specifically includes Cyclospora and report confirmed cases through appropriate public health channels.

Caveats: CDC discontinued weekly updates because recent infections declined, but additional reports are expected. Reporting typically lags symptom onset by approximately six weeks, and thousands of cases still require exposure classification.

CDC surveillance update

4. Recall expands to the alfalfa seed lot implicated in E. coli and Salmonella outbreaks

What changed: The supplier of the seed used by Everything Sprouts agreed to recall the implicated alfalfa seed lot. The seed had been distributed to sprout growers and wholesalers in 16 states, Puerto Rico, Canada, Mexico, Tahiti, and Venezuela.

Why it matters for clinicians: Recalling the source seed broadens the response beyond previously identified packaged sprouts and may identify additional growers or products. The investigation includes 55 illnesses, four hospitalizations, multiple Shiga toxin-producing E. coli serotypes, and Salmonella Agona.

Practical clinical relevance: Patients with relevant exposure and bloody diarrhea, severe abdominal pain, fever, dehydration, or signs of hemolytic uremic syndrome require prompt evaluation. Retailers, distributors, and growers should identify and discard implicated seeds and sprouts and sanitize affected surfaces.

Caveats: The September 15 development concerns the seed recall and distribution network; reported illness counts were not newly increased. The identified sprouts do not explain every outbreak-associated illness, and the investigation remains open.

FDA outbreak update

5. CDC updates a separate Salmonella outbreak linked to broccoli sprouts

What changed: CDC linked a separate Salmonella outbreak to Evergreen Fresh Sprouts broccoli sprouts recalled on September 10. Products were distributed to food cooperatives, restaurants, food-service customers, and grocery stores in Idaho, Montana, and Washington, with possible wider distribution.

Why it matters for clinicians: This outbreak is not considered part of the multistate alfalfa sprout investigation. Sprouts pose particular food-safety challenges because warm, humid growing conditions can amplify bacterial contamination.

Practical clinical relevance: Recalled sprouts should not be eaten, sold, or served. Consider Salmonella in patients with diarrhea, fever, and abdominal cramping, especially when illness is severe or occurs in children younger than 5 years, adults age 65 years or older, or immunocompromised patients.

Caveats: CDC’s September 11 notice focused on the recall and exposure response rather than providing a complete national case summary. Distribution and case identification may continue to evolve.

CDC outbreak alert

6. Real-world evidence supports nirsevimab effectiveness against severe infant RSV

What changed: A test-negative case-control study examined 1,942 infant hospital encounters in Ontario and Quebec during the 2024-2025 RSV season. Estimated nirsevimab effectiveness was 77% against emergency department visits, 79% against hospitalization, and 97% against ICU admission.

Why it matters for clinicians: The findings extend randomized trial evidence by demonstrating substantial effectiveness during routine population-wide use.

Practical clinical relevance: Identify eligible infants before or during their first RSV season and coordinate infant protection with maternal RSV vaccination history. Timely administration, documentation, and communication between maternity, pediatric, and primary care services remain important.

Caveats: This was an observational study, and residual differences between treated and untreated infants remain possible. The ICU estimate was based on relatively few immunized cases and therefore had wider uncertainty. Results reflect two Canadian provinces and one RSV season.

JAMA Network Open source

7. Intrauterine mepivacaine reduces pain during IUD placement

What changed: A double-blind trial randomized 370 nulliparous patients to 10 mL of intrauterine mepivacaine or saline before IUD placement. Mean pain scores were 43.8 versus 58.6 on a 100-mm scale, an adjusted difference of 14.2 mm.

Why it matters for clinicians: Pain concerns can deter patients from selecting an IUD. The intervention offers a potentially simple, locally administered option that produced a clinically relevant reduction in procedural pain.

Practical clinical relevance: The anesthetic was delivered through a catheter two minutes before placement. If adopted, clinics will need protocols for dosing, allergy assessment, toxicity precautions, medication handling, and the additional procedural step.

Caveats: Participants were age 18 to 31 years, nulliparous, and receiving IUDs with smaller placement tubes in Swedish clinics. Comparative effectiveness against paracervical block, lidocaine, NSAIDs, or multimodal analgesia was not established.

JAMA source

8. Early IVIG improves short-term outcomes in newly diagnosed inflammatory myopathy

What changed: A double-blind trial randomized 44 adults with newly diagnosed idiopathic inflammatory myopathy to IVIG or placebo in addition to high-dose prednisone. Mean Total Improvement Score at 12 weeks was 60.0 with IVIG versus 42.5 with placebo.

Why it matters for clinicians: Moderate improvement occurred in 91% versus 53%, and major improvement in 70% versus 26%. Median time to moderate improvement was four versus 12 weeks, suggesting a role for faster initial disease control.

Practical clinical relevance: Early IVIG may be considered in specialist care for selected patients with severe weakness, dysphagia, respiratory involvement, or a need for rapid improvement. Thrombosis, renal dysfunction, hemolysis, infusion reactions, product supply, and cost require consideration.

Caveats: This was a small, single-center trial with short follow-up and a composite disease-activity endpoint. One asymptomatic deep venous thrombosis occurred in the IVIG group. Steroid-sparing and long-term functional effects remain uncertain.

JAMA Neurology source

9. Carotid revascularization does not improve cognition in asymptomatic stenosis

What changed: Prespecified secondary cognitive outcomes from the CREST-2 randomized trials included 2,165 patients with at least 70% asymptomatic carotid stenosis. Neither carotid artery stenting nor carotid endarterectomy plus intensive medical therapy improved four-year cognitive scores relative to intensive medical therapy alone.

Why it matters for clinicians: Cognitive concerns are sometimes proposed as a reason to intervene in otherwise asymptomatic stenosis. The findings do not support revascularization for the purpose of improving cognition.

Practical clinical relevance: Revascularization decisions should remain centered on stroke-prevention benefit, procedural risk, life expectancy, anatomy, and the effectiveness of contemporary medical management.

Caveats: Cognition was a secondary outcome and was assessed largely through telephone-administered tests. Mean follow-up testing was shorter than four years for many participants, and the findings do not resolve every question regarding selected patients with impaired cerebral hemodynamics.

JAMA source

10. Semaglutide benefits appear consistent across frailty categories

What changed: A post hoc analysis of the 17,604-participant SELECT trial evaluated semaglutide in adults with cardiovascular disease and overweight or obesity but without diabetes. Reductions in adverse cardiovascular outcomes did not show statistically detectable heterogeneity across baseline frailty groups.

Why it matters for clinicians: Frailty frequently complicates obesity treatment decisions. Participants with greater frailty also reported larger quality-of-life improvements, and semaglutide was associated with a greater likelihood of improvement rather than worsening in frailty status.

Practical clinical relevance: Frailty alone should not automatically exclude an otherwise eligible patient. Treatment still requires gradual titration and monitoring for gastrointestinal intolerance, volume depletion, loss of lean mass, nutritional compromise, gallbladder disease, and other labeled risks.

Caveats: Frailty analyses were secondary and post hoc. SELECT excluded patients with diabetes and may underrepresent very frail, institutionalized, or clinically unstable adults. The analysis does not establish that semaglutide treats frailty itself.

JAMA Cardiology source

11. Adjunctive azithromycin adoption was followed by fewer postpartum infections

What changed: An analysis of 1.7 million births found that, after publication of a 2016 randomized trial, azithromycin use increased by 37.6 percentage points for unscheduled cesarean deliveries relative to vaginal births. Postpartum infections decreased by 2.0 percentage points.

Why it matters for clinicians: The findings suggest that the randomized evidence translated into clinical practice and population-level improvement outside trial settings.

Practical clinical relevance: Eligible patients undergoing cesarean delivery during labor or after membrane rupture should receive guideline-concordant prophylaxis, generally including adjunctive azithromycin in addition to standard cephalosporin prophylaxis when appropriate.

Caveats: This was a difference-in-differences observational analysis, not a new randomized comparison. Concurrent practice changes, coding limitations, drug allergies, local resistance patterns, and antimicrobial stewardship remain relevant.

JAMA source

12. Meta-analysis raises concern about immunotherapy when PD-L1 CPS is below 1

What changed: A Bayesian meta-analysis of seven phase 3 trials involving 630 patients with head and neck squamous cell carcinoma and PD-L1 combined positive score below 1 found a high probability of reduced survival with immune checkpoint inhibitors.

Why it matters for clinicians: In recurrent or metastatic disease, the frequentist overall survival estimate also favored control therapy. This suggests that biomarker-negative patients may not share the benefits observed in broader or PD-L1-positive populations.

Practical clinical relevance: Confirm PD-L1 testing methodology and CPS before treatment selection. For CPS below 1, treatment should be individualized according to disease setting, approved labeling, chemotherapy fitness, prior therapy, and current guidelines.

Caveats: The analysis relied on published trial subgroups rather than prospectively randomized CPS-specific populations. Trial regimens and disease settings differed, and Bayesian estimates depend partly on modeling assumptions. The findings should prompt caution and prospective validation rather than immediate universal withdrawal of immunotherapy.

JAMA Oncology source

13. HPV16-targeted immunotherapy shows early activity with pembrolizumab

What changed: In the phase 2 VERSATILE-002 nonrandomized trial, PDS0101 plus pembrolizumab produced a 34% response rate among 53 checkpoint inhibitor-naive patients with recurrent or metastatic HPV16-positive head and neck cancer. Median progression-free survival was 5.3 months.

Why it matters for clinicians: The strategy combines an HPV16-targeted therapeutic immunotherapy with checkpoint inhibition and may enhance antitumor immunity in a biomarker-selected population.

Practical clinical relevance: PDS0101 remains investigational and should be used through clinical trials. HPV status, PD-L1 expression, disease burden, prior therapy, performance status, and approved first-line options remain central to treatment planning.

Caveats: There was no randomized comparator, and the modified intention-to-treat efficacy population was small. No responses occurred among 22 checkpoint inhibitor-resistant participants, arguing against assuming that the combination reverses established resistance.

JAMA Oncology source

14. Targeted human milk fortification does not improve neonatal outcomes

What changed: A double-blind trial randomized 130 human milk-fed infants born at 24 to 30 weeks to individualized fortification guided by point-of-care milk analysis or standard fortification. Growth, body composition, and brain MRI measures did not significantly differ.

Why it matters for clinicians: Point-of-care milk analysis adds equipment, testing, labor, and cost. The trial does not support its routine use when contemporary standard fortification already achieves recommended nutrient intake.

Practical clinical relevance: NICUs should continue individualized clinical monitoring of weight, length, head growth, feeding tolerance, laboratory markers, and growth faltering. Additional protein or energy can still be provided when clinically indicated.

Caveats: The trial was conducted at a single academic NICU, and both groups received relatively high nutrient intake. Findings may not apply where baseline fortification is less intensive, milk composition differs, or targeted analysis is used for selected infants rather than universally.

JAMA Pediatrics source

15. Evidence supporting cisplatin over carboplatin varies by tumor type

What changed: An umbrella analysis synthesized 11 meta-analyses, 52 unique studies, and 12,683 patients across seven tumor types. High-certainty evidence was limited to better radiologic response with cisplatin in advanced urothelial cancer and no clear progression-free survival difference in ovarian cancer.

Why it matters for clinicians: Cisplatin and carboplatin are not universally interchangeable, but the assumption that cisplatin is always more effective is also not supported by high-certainty evidence across all cancers.

Practical clinical relevance: Selection should account for tumor type, treatment intent, regimen-specific evidence, kidney function, hearing, neuropathy, emesis risk, marrow reserve, performance status, and patient preferences.

Caveats: Most efficacy and toxicity comparisons were low or very low certainty. The underlying meta-analyses included heterogeneous regimens and older studies. Cisplatin caused more nonhematologic toxicity, while carboplatin caused more hematologic toxicity, but comparative toxicity certainty was limited.

JAMA Network Open source

16. Statin initiation after colorectal cancer treatment provides little evidence of cancer-specific benefit

What changed: A Korean target-trial emulation included 88,516 adults treated for colorectal cancer, of whom 2,071 initiated a statin within six months. The standardized difference in 60-month colorectal cancer-specific survival was 1.1 percentage points and was not statistically significant.

Why it matters for clinicians: Previous observational studies may have overstated anticancer benefit because of immortal-time bias, treatment selection, and informative censoring.

Practical clinical relevance: Statins should not be started solely to improve colorectal cancer survival. They should remain available when indicated for atherosclerotic cardiovascular risk reduction or another established reason.

Caveats: This was not a randomized trial. Claims data incompletely capture cancer stage, recurrence, adherence, lifestyle factors, and treatment details, and the Korean health system may limit generalizability.

JAMA Network Open source

17. RSV mortality beyond infancy is concentrated among medically complex children

What changed: A multicenter retrospective cohort identified 6,430 RSV-associated ICU admissions among children age 2 to 17 years. Hospital mortality was 7.5%, and this age group accounted for approximately two-thirds of RSV-associated pediatric ICU deaths across all ages.

Why it matters for clinicians: At least one complex chronic condition was present in 57.2% of admissions and 93.8% of deaths. Malignancy, neurologic disease, chronic respiratory disease, transplantation, technology dependence, and multiple affected organ systems were associated with higher mortality.

Practical clinical relevance: Maintain a low threshold for early assessment and escalation in medically complex children with suspected RSV. Respiratory-season planning should include testing, caregiver counseling, escalation pathways, and careful review of available prevention eligibility.

Caveats: The study used retrospective diagnosis and procedure data from 2017 through 2023. It did not test a preventive intervention and does not establish new prophylaxis recommendations for older children.

JAMA Network Open source

18. Most children with febrile seizures have comparable school performance

What changed: A Danish nationwide cohort compared 26,173 children with febrile seizures with 645,946 unaffected children. Reading and mathematics scores differed only minimally overall.

Why it matters for clinicians: The findings provide useful reassurance for families concerned about long-term cognitive or academic harm after typical febrile seizures.

Practical clinical relevance: Routine educational testing solely because of a single or uncomplicated febrile seizure is not supported. Children with numerous recurrent hospital contacts, developmental concerns, or subsequent epilepsy may merit closer developmental and educational follow-up.

Caveats: Performance declined with increasing numbers of febrile seizure-related hospital contacts, and children who developed epilepsy had larger score differences. Registry data cannot fully characterize seizure type, duration, treatment, or unmeasured family and developmental factors.

JAMA Network Open source

19. Unit-level ESBL colonization pressure predicts neonatal acquisition

What changed: Repeated screening in 24 neonatal units across eight European countries included 1,847 infants. Higher prevalence of ESBL-harboring bacteria within a unit was associated with greater odds that an individual infant would acquire ESBL colonization.

Why it matters for clinicians: Risk persisted after accounting for prematurity, length of stay, antibiotic exposure, and unit effects. This supports viewing antimicrobial-resistant organism acquisition as a unit-wide transmission problem rather than solely an individual patient risk.

Practical clinical relevance: NICUs should reinforce hand hygiene, environmental cleaning, equipment practices, antimicrobial stewardship, cohorting or isolation when indicated, and timely investigation of increasing colonization rates.

Caveats: The study used repeated cross-sectional sampling and PCR detection of resistance genes rather than continuous patient-level transmission mapping. Colonization is not equivalent to clinical infection, and the study does not identify one preferred screening or isolation strategy.

JAMA Network Open source

20. WHO validates elimination of dog-transmitted rabies in Chile

What changed: WHO validated Chile as the first South American country to eliminate dog-transmitted rabies as a public health problem. Chile’s last reported human case transmitted by a dog occurred in 1972.

Why it matters for clinicians: The achievement demonstrates the effectiveness of sustained animal vaccination, laboratory surveillance, community education, border risk management, and reliable access to human post-exposure prophylaxis.

Practical clinical relevance: Validation does not change the need for immediate wound cleansing, exposure assessment, rabies vaccination, and rabies immunoglobulin when indicated after a potentially rabid animal exposure.

Caveats: Elimination does not mean that all rabies virus circulation has ended or that reintroduction is impossible. Continued animal surveillance, vaccination, laboratory capacity, and rapid response remain necessary.

WHO source